Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies

Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, Stefan Leucht, Mark Olfson, John M. Kane, Christoph U. Correll

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs) should improve medication adherence and reduce relapses in schizophrenia. However, meta-analyses of randomized trials and mirror-image studies yielded inconsistent results. Nonrandomized cohort studies with parallel comparisons of LAIs and OAPs offer a third design to examine this issue. We meta-analyzed cohort studies with ≥24 weeks duration and hospitalization data. Primary outcome was hospitalization rate, ie, number of hospitalizations per person-year. Secondary outcomes included hospitalization risk, ie, proportion of patients experiencing ≥1 hospitalizations, all-cause discontinuation, and total hospitalization days. Patient severity and/or chronicity at baseline was also meta-analyzed and explored as a potential effect size moderator. Altogether, 42 studies (n = 101 624; follow-up = 18.6 ± 10.0 mo) were meta-analyzed. LAIs were superior to OAPs regarding hospitalization rate (studies = 15, person-years = 68 009, rate ratio = 0.85, 95% CI = 0.78-0.93, P < .001) and all-cause discontinuations (studies = 10, n = 37 293, risk ratio = 0.78, 95% CI = 0.67-0.91, P = .001), but not regarding hospitalization risk (studies = 33, n = 51 733, risk ratio = 0.92, 95% CI = 0.84-1.00, P = .06), and hospitalization days (studies = 11, n = 21 328, Hedges' g = -0.05, 95% CI = -0.16 to 0.06, P = .39). Illness severity/chronicity was significantly greater in patients prescribed LAIs vs OAPs when all available information was pooled together (studies = 23, n = 61 806, Hedges' g = 0.15, 95% CI = 0.03-0.26, P = .01), but not when examined separately. In summary, this metaanalysis of cohort studies, which included patients that are broadly representative of clinical practice, indicates that LAIs are superior to OAPs. The lack of significant superiority of LAIs for hospitalization risk and hospital days needs to be interpreted in the context of naturalistic treatment selection with subsequently greater illness severity/chronicity in LAI-treated patients.

Original languageEnglish
Pages (from-to)603-619
Number of pages17
JournalSchizophrenia Bulletin
Volume44
Issue number3
DOIs
Publication statusPublished - 2018 Apr 6

Fingerprint

Antipsychotic Agents
Meta-Analysis
Schizophrenia
Hospitalization
Cohort Studies
Retrospective Studies
Injections
Odds Ratio
Patient Advocacy
Medication Adherence
Recurrence

Keywords

  • depot
  • hospitalization
  • maintenance therapy
  • moderators
  • psychosis
  • treatment discontinuation

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia : A Meta-analysis of Prospective and Retrospective Cohort Studies. / Kishimoto, Taishiro; Hagi, Katsuhiko; Nitta, Masahiro; Leucht, Stefan; Olfson, Mark; Kane, John M.; Correll, Christoph U.

In: Schizophrenia Bulletin, Vol. 44, No. 3, 06.04.2018, p. 603-619.

Research output: Contribution to journalArticle

Kishimoto, Taishiro ; Hagi, Katsuhiko ; Nitta, Masahiro ; Leucht, Stefan ; Olfson, Mark ; Kane, John M. ; Correll, Christoph U. / Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia : A Meta-analysis of Prospective and Retrospective Cohort Studies. In: Schizophrenia Bulletin. 2018 ; Vol. 44, No. 3. pp. 603-619.
@article{10ed13635ec8404387ba268b04fb9d6d,
title = "Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies",
abstract = "Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs) should improve medication adherence and reduce relapses in schizophrenia. However, meta-analyses of randomized trials and mirror-image studies yielded inconsistent results. Nonrandomized cohort studies with parallel comparisons of LAIs and OAPs offer a third design to examine this issue. We meta-analyzed cohort studies with ≥24 weeks duration and hospitalization data. Primary outcome was hospitalization rate, ie, number of hospitalizations per person-year. Secondary outcomes included hospitalization risk, ie, proportion of patients experiencing ≥1 hospitalizations, all-cause discontinuation, and total hospitalization days. Patient severity and/or chronicity at baseline was also meta-analyzed and explored as a potential effect size moderator. Altogether, 42 studies (n = 101 624; follow-up = 18.6 ± 10.0 mo) were meta-analyzed. LAIs were superior to OAPs regarding hospitalization rate (studies = 15, person-years = 68 009, rate ratio = 0.85, 95{\%} CI = 0.78-0.93, P < .001) and all-cause discontinuations (studies = 10, n = 37 293, risk ratio = 0.78, 95{\%} CI = 0.67-0.91, P = .001), but not regarding hospitalization risk (studies = 33, n = 51 733, risk ratio = 0.92, 95{\%} CI = 0.84-1.00, P = .06), and hospitalization days (studies = 11, n = 21 328, Hedges' g = -0.05, 95{\%} CI = -0.16 to 0.06, P = .39). Illness severity/chronicity was significantly greater in patients prescribed LAIs vs OAPs when all available information was pooled together (studies = 23, n = 61 806, Hedges' g = 0.15, 95{\%} CI = 0.03-0.26, P = .01), but not when examined separately. In summary, this metaanalysis of cohort studies, which included patients that are broadly representative of clinical practice, indicates that LAIs are superior to OAPs. The lack of significant superiority of LAIs for hospitalization risk and hospital days needs to be interpreted in the context of naturalistic treatment selection with subsequently greater illness severity/chronicity in LAI-treated patients.",
keywords = "depot, hospitalization, maintenance therapy, moderators, psychosis, treatment discontinuation",
author = "Taishiro Kishimoto and Katsuhiko Hagi and Masahiro Nitta and Stefan Leucht and Mark Olfson and Kane, {John M.} and Correll, {Christoph U.}",
year = "2018",
month = "4",
day = "6",
doi = "10.1093/schbul/sbx090",
language = "English",
volume = "44",
pages = "603--619",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia

T2 - A Meta-analysis of Prospective and Retrospective Cohort Studies

AU - Kishimoto, Taishiro

AU - Hagi, Katsuhiko

AU - Nitta, Masahiro

AU - Leucht, Stefan

AU - Olfson, Mark

AU - Kane, John M.

AU - Correll, Christoph U.

PY - 2018/4/6

Y1 - 2018/4/6

N2 - Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs) should improve medication adherence and reduce relapses in schizophrenia. However, meta-analyses of randomized trials and mirror-image studies yielded inconsistent results. Nonrandomized cohort studies with parallel comparisons of LAIs and OAPs offer a third design to examine this issue. We meta-analyzed cohort studies with ≥24 weeks duration and hospitalization data. Primary outcome was hospitalization rate, ie, number of hospitalizations per person-year. Secondary outcomes included hospitalization risk, ie, proportion of patients experiencing ≥1 hospitalizations, all-cause discontinuation, and total hospitalization days. Patient severity and/or chronicity at baseline was also meta-analyzed and explored as a potential effect size moderator. Altogether, 42 studies (n = 101 624; follow-up = 18.6 ± 10.0 mo) were meta-analyzed. LAIs were superior to OAPs regarding hospitalization rate (studies = 15, person-years = 68 009, rate ratio = 0.85, 95% CI = 0.78-0.93, P < .001) and all-cause discontinuations (studies = 10, n = 37 293, risk ratio = 0.78, 95% CI = 0.67-0.91, P = .001), but not regarding hospitalization risk (studies = 33, n = 51 733, risk ratio = 0.92, 95% CI = 0.84-1.00, P = .06), and hospitalization days (studies = 11, n = 21 328, Hedges' g = -0.05, 95% CI = -0.16 to 0.06, P = .39). Illness severity/chronicity was significantly greater in patients prescribed LAIs vs OAPs when all available information was pooled together (studies = 23, n = 61 806, Hedges' g = 0.15, 95% CI = 0.03-0.26, P = .01), but not when examined separately. In summary, this metaanalysis of cohort studies, which included patients that are broadly representative of clinical practice, indicates that LAIs are superior to OAPs. The lack of significant superiority of LAIs for hospitalization risk and hospital days needs to be interpreted in the context of naturalistic treatment selection with subsequently greater illness severity/chronicity in LAI-treated patients.

AB - Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs) should improve medication adherence and reduce relapses in schizophrenia. However, meta-analyses of randomized trials and mirror-image studies yielded inconsistent results. Nonrandomized cohort studies with parallel comparisons of LAIs and OAPs offer a third design to examine this issue. We meta-analyzed cohort studies with ≥24 weeks duration and hospitalization data. Primary outcome was hospitalization rate, ie, number of hospitalizations per person-year. Secondary outcomes included hospitalization risk, ie, proportion of patients experiencing ≥1 hospitalizations, all-cause discontinuation, and total hospitalization days. Patient severity and/or chronicity at baseline was also meta-analyzed and explored as a potential effect size moderator. Altogether, 42 studies (n = 101 624; follow-up = 18.6 ± 10.0 mo) were meta-analyzed. LAIs were superior to OAPs regarding hospitalization rate (studies = 15, person-years = 68 009, rate ratio = 0.85, 95% CI = 0.78-0.93, P < .001) and all-cause discontinuations (studies = 10, n = 37 293, risk ratio = 0.78, 95% CI = 0.67-0.91, P = .001), but not regarding hospitalization risk (studies = 33, n = 51 733, risk ratio = 0.92, 95% CI = 0.84-1.00, P = .06), and hospitalization days (studies = 11, n = 21 328, Hedges' g = -0.05, 95% CI = -0.16 to 0.06, P = .39). Illness severity/chronicity was significantly greater in patients prescribed LAIs vs OAPs when all available information was pooled together (studies = 23, n = 61 806, Hedges' g = 0.15, 95% CI = 0.03-0.26, P = .01), but not when examined separately. In summary, this metaanalysis of cohort studies, which included patients that are broadly representative of clinical practice, indicates that LAIs are superior to OAPs. The lack of significant superiority of LAIs for hospitalization risk and hospital days needs to be interpreted in the context of naturalistic treatment selection with subsequently greater illness severity/chronicity in LAI-treated patients.

KW - depot

KW - hospitalization

KW - maintenance therapy

KW - moderators

KW - psychosis

KW - treatment discontinuation

UR - http://www.scopus.com/inward/record.url?scp=85041511582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041511582&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbx090

DO - 10.1093/schbul/sbx090

M3 - Article

C2 - 29868849

AN - SCOPUS:85041511582

VL - 44

SP - 603

EP - 619

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 3

ER -